Tempus AI/$TEM
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Tempus AI
Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.
Ticker
$TEM
Sector
Primary listing
Employees
2,400
Headquarters
Website
Tempus AI Metrics
BasicAdvanced
$15B
-
-$1.18
-
-
Price and volume
Market cap
$15B
52-week high
$91.45
52-week low
$31.36
Average daily volume
11M
Financial strength
Current ratio
1.541
Quick ratio
1.333
Long term debt to equity
272.602
Total debt to equity
275.632
Interest coverage (TTM)
-3.44%
Profitability
EBITDA (TTM)
-161.904
Gross margin (TTM)
60.70%
Net profit margin (TTM)
-20.98%
Operating margin (TTM)
-24.09%
Effective tax rate (TTM)
18.66%
Revenue per employee (TTM)
$400,000
Management effectiveness
Return on assets (TTM)
-11.51%
Return on equity (TTM)
-97.95%
Valuation
Price to revenue (TTM)
15.38
Price to book
48.45
Price to tangible book (TTM)
-37.14
Price to free cash flow (TTM)
-200.748
Free cash flow yield (TTM)
-0.50%
Free cash flow per share (TTM)
-0.431
Growth
Revenue change (TTM)
59.84%
Earnings per share change (TTM)
-89.83%
Bulls say / Bears say
Tempus exceeded Q1 2025 revenue expectations with a 75.4% year-over-year rise to $255.7 million and raised its full-year 2025 outlook to $1.25 billion, aiming for positive Adjusted EBITDA, signaling strong financial momentum (Investing.com turn11search1).
The company announced multi-year partnerships with AstraZeneca and Pathos to develop the largest multimodal foundation model in oncology, securing $200 million in data licensing and model development fees, underlining significant demand for its AI-driven platform (Reuters turn5view0).
Tempus signed a deal with Boehringer Ingelheim on May 14, 2025, granting access to its de-identified molecular, clinical, and imaging datasets via the Lens AI platform for cancer R&D, broadening its high-value pharmaceutical partnerships (Investing.com turn7search1).
Shares dropped 16.9% pre-market after Tempus posted Q4 revenue of $200.7 million, below the $203.1 million expected by analysts, highlighting operational risks and market sensitivity (Reuters turn10search6).
A report by short-seller Spruce Point led to a 16.4% share decline, alleging aggressive accounting practices, financial engineering, related-party deals, and warned of a possible 50–60% downside risk due to questionable earnings quality (Reuters turn8search3).
Spruce Point also noted that AI Applications revenue was only $12.4 million in 2024—less than 2% of total revenue—raising doubts about Tempus’s AI-driven growth story (Investing.com turn8search1).
Data summarised monthly by Lightyear AI. Last updated on 3 Sept 2025.
Tempus AI News
AllArticlesVideos
Tempus AI Gains FDA Clearance For Updated Pixel To Boost Accuracy And Efficiency In Cardiac Imaging
Benzinga1 week ago
Tempus AI Surges, Flirting With A Profit-Taking Zone, On A Fresh FDA Move
Investors Business Daily1 week ago
Tempus Receives U.S. FDA Special 510(k) Clearance for Updated Tempus Pixel Device
Business Wire1 week ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Tempus AI stock?
Tempus AI (TEM) has a market cap of $15B as of September 19, 2025.
What is the P/E ratio for Tempus AI stock?
The price to earnings (P/E) ratio for Tempus AI (TEM) stock is 0 as of September 19, 2025.
Does Tempus AI stock pay dividends?
No, Tempus AI (TEM) stock does not pay dividends to its shareholders as of September 19, 2025.
When is the next Tempus AI dividend payment date?
Tempus AI (TEM) stock does not pay dividends to its shareholders.
What is the beta indicator for Tempus AI?
Tempus AI (TEM) does not currently have a Beta indicator.